SG11201912881SA - Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide - Google Patents
Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamideInfo
- Publication number
- SG11201912881SA SG11201912881SA SG11201912881SA SG11201912881SA SG11201912881SA SG 11201912881S A SG11201912881S A SG 11201912881SA SG 11201912881S A SG11201912881S A SG 11201912881SA SG 11201912881S A SG11201912881S A SG 11201912881SA SG 11201912881S A SG11201912881S A SG 11201912881SA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazol
- ylmethyl
- pyridin
- acetamide
- cyclopropyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017066806 | 2017-07-05 | ||
| PCT/EP2018/068087 WO2019008034A1 (en) | 2017-07-05 | 2018-07-04 | Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201912881SA true SG11201912881SA (en) | 2020-01-30 |
Family
ID=63079885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201912881SA SG11201912881SA (en) | 2017-07-05 | 2018-07-04 | Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11059803B2 (en) |
| EP (1) | EP3649117A1 (en) |
| JP (2) | JP2020525475A (en) |
| KR (1) | KR102645911B1 (en) |
| CN (1) | CN110831932A (en) |
| AU (1) | AU2018296423B2 (en) |
| BR (1) | BR112020000099A2 (en) |
| CA (1) | CA3067489A1 (en) |
| CL (1) | CL2020000002A1 (en) |
| EA (1) | EA202090193A1 (en) |
| IL (1) | IL271764B2 (en) |
| MA (1) | MA50972A (en) |
| PH (1) | PH12020500040A1 (en) |
| SG (1) | SG11201912881SA (en) |
| UA (1) | UA126582C2 (en) |
| WO (1) | WO2019008034A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3554490T3 (en) | 2016-12-16 | 2022-05-30 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising a t-type calcium channel blocker |
| MA47409A (en) | 2017-02-06 | 2019-12-11 | Idorsia Pharmaceuticals Ltd | NEW PROCESS FOR THE SYNTHESIS OF 1-ARYL-1-TRIFLUOROMETHYLCYCLOPROPANES |
| KR102645911B1 (en) * | 2017-07-05 | 2024-03-08 | 이도르시아 파마슈티컬스 리미티드 | N-[1-(5-cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-ah Crystalline Form of Setamide |
| CA3161908A1 (en) | 2019-12-20 | 2021-06-24 | Michael Ambuehl | Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide |
| WO2023240205A1 (en) | 2022-06-10 | 2023-12-14 | Neurocrine Biosciences, Inc. | Deuterated compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR100712A1 (en) * | 2014-06-03 | 2016-10-26 | Actelion Pharmaceuticals Ltd | PIRAZOL COMPOUNDS AS BLOCKERS OF TYPE T CALCIUM CHANNELS |
| MX367519B (en) | 2014-09-15 | 2019-08-26 | Idorsia Pharmaceuticals Ltd | Triazole compounds as t-type calcium channel blockers. |
| PL3554490T3 (en) | 2016-12-16 | 2022-05-30 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising a t-type calcium channel blocker |
| MA47409A (en) | 2017-02-06 | 2019-12-11 | Idorsia Pharmaceuticals Ltd | NEW PROCESS FOR THE SYNTHESIS OF 1-ARYL-1-TRIFLUOROMETHYLCYCLOPROPANES |
| KR102645911B1 (en) * | 2017-07-05 | 2024-03-08 | 이도르시아 파마슈티컬스 리미티드 | N-[1-(5-cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-ah Crystalline Form of Setamide |
-
2018
- 2018-07-04 KR KR1020207002894A patent/KR102645911B1/en active IP Right Grant
- 2018-07-04 AU AU2018296423A patent/AU2018296423B2/en active Active
- 2018-07-04 BR BR112020000099-0A patent/BR112020000099A2/en active Search and Examination
- 2018-07-04 IL IL271764A patent/IL271764B2/en unknown
- 2018-07-04 SG SG11201912881SA patent/SG11201912881SA/en unknown
- 2018-07-04 WO PCT/EP2018/068087 patent/WO2019008034A1/en unknown
- 2018-07-04 CA CA3067489A patent/CA3067489A1/en active Pending
- 2018-07-04 CN CN201880044771.7A patent/CN110831932A/en active Pending
- 2018-07-04 UA UAA202000506A patent/UA126582C2/en unknown
- 2018-07-04 MA MA050972A patent/MA50972A/en unknown
- 2018-07-04 US US16/628,618 patent/US11059803B2/en active Active
- 2018-07-04 JP JP2019572102A patent/JP2020525475A/en active Pending
- 2018-07-04 EP EP18749304.4A patent/EP3649117A1/en active Pending
- 2018-07-04 EA EA202090193A patent/EA202090193A1/en unknown
-
2020
- 2020-01-02 CL CL2020000002A patent/CL2020000002A1/en unknown
- 2020-01-03 PH PH12020500040A patent/PH12020500040A1/en unknown
-
2021
- 2021-06-11 US US17/345,844 patent/US11555025B2/en active Active
-
2023
- 2023-06-26 JP JP2023104050A patent/JP2023123679A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020000099A2 (en) | 2020-07-07 |
| EA202090193A1 (en) | 2020-06-03 |
| EP3649117A1 (en) | 2020-05-13 |
| KR20200018698A (en) | 2020-02-19 |
| WO2019008034A1 (en) | 2019-01-10 |
| IL271764B1 (en) | 2023-06-01 |
| CL2020000002A1 (en) | 2020-07-31 |
| US11555025B2 (en) | 2023-01-17 |
| US11059803B2 (en) | 2021-07-13 |
| PH12020500040A1 (en) | 2020-10-12 |
| AU2018296423B2 (en) | 2022-07-28 |
| IL271764A (en) | 2020-02-27 |
| KR102645911B1 (en) | 2024-03-08 |
| US20210300894A1 (en) | 2021-09-30 |
| MA50972A (en) | 2020-10-14 |
| IL271764B2 (en) | 2023-10-01 |
| UA126582C2 (en) | 2022-11-02 |
| JP2020525475A (en) | 2020-08-27 |
| CA3067489A1 (en) | 2019-01-10 |
| AU2018296423A1 (en) | 2020-02-20 |
| JP2023123679A (en) | 2023-09-05 |
| US20200165221A1 (en) | 2020-05-28 |
| CN110831932A (en) | 2020-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271764A (en) | Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide | |
| IL266214A (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| IL274488A (en) | Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| HK1245019A1 (en) | Use of picolinamide compounds as fungicides | |
| IL257390B (en) | Salts of 1-((4-(methoxymethyl)-4-(((1r,2s)-2-phenyl-cyclopropylamine)methyl) piperidin-1-yl)methyl)-cyclobutane-carboxylic acid as lsd1 inhibitor | |
| GB201609607D0 (en) | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts | |
| HK1259405A1 (en) | New crystalline form of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide | |
| GB201609603D0 (en) | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide | |
| IL279151A (en) | Inhibitors of integrated stress response pathway | |
| ZA201907022B (en) | Reduction of regenerator clogging | |
| IL266003A (en) | Salts of indazole derivative and crystals thereof | |
| IL285675A (en) | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate | |
| SI3099302T1 (en) | Crystalline forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide | |
| GB2571529B (en) | Formation of piezoelectric devices | |
| ZA202003028B (en) | Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative | |
| SG11202103847QA (en) | Estimation of asymmetric aberrations | |
| PT3643704T (en) | New intermediates for the preparation of remifentanil hydrochloride | |
| HK1257520A1 (en) | Herbicidal compositions containing 2-chloro-3-(methylsulfanyl)-n-(1-methyl-1h-tetrazole-5-yl)-4-(trifluoromethyl)benzamide | |
| IT201700050223A1 (en) | PROCEDURE FOR THE PREPARATION OF CRYSTALLINE DEXLANSOPRAZOLE | |
| IL249496A0 (en) | Improved process for preparation of 4-(1-(4-(perfluoroethoxy)phenyl)-1h-1,2,4-triazol-3-yl)benzoyl azide | |
| GB201621528D0 (en) | Use of trpv1 agonist | |
| GB201705905D0 (en) | Pack of disposable wipes | |
| GB201600013D0 (en) | Domperidone medicine intermediate 1-(30chloropropyl)-benzimidazol-2-one synthesis method |